Sarah Medeiros's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership • Q2 2025
Question
Sarah Medeiros of Cantor Fitzgerald asked how FEV1 data would be presented, considering patient baselines, and what other measurements, such as quality of life, would be used to support the CF program's efficacy.
Answer
President and CEO Joseph Payne explained they will analyze FEV1 using an "area under the curve" approach and noted that most participants have a baseline FEV1 in the 60-80% range. He also confirmed the use of the standardized CF Questionnaire-Revised (CFQ-R) to measure quality of life, providing an additional supportive endpoint.